This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Stomp the S&P With 5 Hated Stocks Ready to Pop

Johnson & Johnson

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

It may seem surprising that a staid blue-chip name such as Johnson & Johnson (JNJ) could top off our list of hated stocks, but investors are piling in against this stock right now. As I write, JNJ's short interest ratio comes in at 10.7, which indicates that it would take more than two full weeks of buying pressure for shorts to exit their bets under current volume levels. That makes this $215 billion health care company a prime candidate for a short squeeze this year.

>>5 Dow Dogs That Could Stomp the Market in 2013

Johnson & Johnson may be best known for its prolific line of consumer medical products, such as Band-Aid bandages and baby shampoo, but its business also includes more complex pharmaceuticals and medical devices as well. In fact, that's a big part of JNJ's big short interest right now, with investors anxious about the pharma industry as a whole thanks to looming patent losses.

But JNJ is one of the best-positioned pharma firms, so its biggest source of profitability isn't in much peril. Meanwhile, the other business units provide stellar diversification in what's already a defensive industry.

Financially, Johnson & Johnson is in stellar shape. The firm carries a $21 billion cash position on its balance sheet, with around $5 billion of that sticking around net of total debt. That gives JNJ plenty of financial security in 2013, and it helps to secure the firm's 3.1% dividend payout right now.

Expect shares' 12.5% rally year-to-date to carry on to the second quarter.

2 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,299.31 +33.32 0.19%
S&P 500 2,010.13 -1.23 -0.06%
NASDAQ 4,572.4620 -20.9630 -0.46%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs